UK To Offer Firms More Flexible Commercial Deals On ‘Transformative’ Drugs, Earlier Access To Market
Companies seeking to have their innovative drugs made available on the NHS in England could benefit from government plans to offer “transformative” new products access to the market up to four years earlier than under the standard assessment route.
You may also be interested in...
UK pharma giant GlaxoSmithKline has nabbed a high-profile figure from Google's Calico to head up its research efforts. Barron's oncology pedigree from his time at Roche suggests that cancer is again a core area for GSK.
A set of proposals in the recently published Life Sciences Industrial Strategy, aimed at improving the way new products are identified and made available under the NHS, reiterates ideas contained in the 2016 Accelerated Access Review. The government says it will respond to the review shortly.
A consultation on plans for the early availability of coronavirus vaccines drew almost 192,000 responses, including a number of concerns to which the government has now responded.